Category: PSMA Therapy in Metastatic prostate

PSMA-PET for individualized radiation treatment of prostate disease

Visitor Edited by Dr Pirus Ghadjar The approach of prostate explicit film antigen (PSMA) positron discharge tomography (PET) imaging has altered radiation treatment of prostate malignant growth. Current radiation treatment plans for prostate malignant growth have been built up by randomized preliminaries utilizing measurable hazard estimations, nomograms and traditional imaging for patient portrayal and treatment.…
Read more

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic emasculation safe prostate malignant growth

We read with intrigue the investigation by Michael S Hofman and colleagues1 announcing results from a solitary arm, stage 2 preliminary of men with metastatic mutilation safe prostate malignant growth who have advanced after traditional treatment who were given intravenous lutetium-177 [177Lu]-prostate-explicit layer antigen (PSMA)- 617 (LuPSMA) radionuclide treatment. This forthcoming preliminary affirmed the promising…
Read more

177Lu-PSMA-617 radioligand treatment in metastatic mutilation safe prostate disease patients with a solitary working kidney.

The point of this examination was to survey the security, passableness and consequences for renal capacity just as helpful viability of prostate-explicit film antigen (PSMA) directed radioligand treatment (PRLT) utilizing lutetium-177 (177Lu) marked PSMA-617 in patients with metastatic mutilation safe prostate malignant growth (mCRPC) and a solitary working kidney before PRLT. Techniques: Sixteen patients (age…
Read more